Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706949 | PMC |
http://dx.doi.org/10.1177/8755122519854855 | DOI Listing |
Pharmaceuticals (Basel)
December 2024
Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34129 Trieste, Italy.
: Biofilm-associated infections frequently span multiple body sites and represent a significant clinical challenge, often requiring a multidisciplinary approach involving surgery and antimicrobial therapy. These infections are commonly healthcare-associated and frequently related to internal or external medical devices. The formation of biofilms complicates treatment, as they create environments that are difficult for most antimicrobial agents to penetrate.
View Article and Find Full Text PDFTuberculosis (Edinb)
December 2024
Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India. Electronic address:
Mycobacterium tuberculosis is a deadly pathogen that claims millions of lives every year. Current research focuses on finding new anti-tuberculosis drugs that are safe and effective, with lesser side effects and toxicity. One important approach is to identify bio-enhancers that can improve the effectiveness of anti-tuberculosis drugs, resulting in reduced doses and shortened treatment times.
View Article and Find Full Text PDFMicrobiology (Reading)
August 2024
Department of Microbial Sciences, School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, GU2 7XH United Kingdom.
Tuberculosis (TB) caused by bacteria of the complex remains one of the most important infectious diseases of mankind. Rifampicin is a first line drug used in multi-drug treatment of TB, however, the necessary duration of treatment with these drugs is long and development of resistance is an increasing impediment to treatment programmes. As a result, there is a requirement for research and development of new TB drugs, which can form the basis of new drug combinations, either due to their own anti-mycobacterial activity or by augmenting the activity of existing drugs such as rifampicin.
View Article and Find Full Text PDFTrials
May 2024
Department of Statistics, ICMR- National Institute for Research in Tuberculosis, Chethpet, Chennai, 600031, India.
Background: Despite several incremental improvements in the management of tuberculous meningitis (TBM), the mortality rates remain high. In spite of national and international guidelines, variation in the choice, dose, and duration of drugs exist between countries and clinicians. We propose to evaluate a shorter and more effective regimen containing agents with augmented intracerebral drug exposure and anti-inflammatory approaches to improve disability-free survival among patients with TBM.
View Article and Find Full Text PDFJ Environ Manage
March 2024
Department of Oral Medicine and Radiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, 600077, Tamil Nadu, India. Electronic address:
A morphological oriented highly active CuO-Ag-CaWO (CAC) nano-heterojunction was fabricated for the visible light driven degradation of rifampicin (RFP). Octahedron shaped CuO being a base material, where the Tagetes shaped CaWO and Ag were embedded on it. The shape-controlled morphology of CuO and CaWO as well as Ag decoration influence high degree of adsorption of RFP and interfacial charge transfer between the nano-heterojunction.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!